Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALB | P02768 | 1/20 | 0.32 |
| ▸ | DNMT1 | P26358 | 3/20 | 0.31 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2611638 | 0.86 | DNMT1 (0.38) | ALBDNMT1ADRB1 | |
| SCHEMBL13597649 | 0.83 | TK1 (0.32) | ALB | |
| SCHEMBL15343693 | 0.83 | POLG (0.46) | — | |
| SCHEMBL20982294 | 0.83 | POLG (0.46) | — | |
| SCHEMBL432197 | 0.83 | POLG (0.46) | — | |
| SCHEMBL24149375 | 0.83 | DNMT1 (0.32) | ALBDNMT1ADRB1 | |
| SCHEMBL2611636 | 0.83 | ALB (0.34) | ALBDNMT1ADRB1 | |
| SCHEMBL2611633 | 0.83 | TK1 (0.38) | — | |
| SCHEMBL2611654 | 0.81 | CA2 (0.41) | — | |
| SCHEMBL22814998 | 0.79 | DNMT1 (0.36) | ALBDNMT1ADRB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160362737-A1 | MODIFIED NUCLEOTIDES | SOLEXA LIMITED (GB) | 2016-12-15 | — | — | US | disclosed |
| US-9388464-B2 | Modified nucleotides | ILLUMINA CAMBRIDGE LIMITED (GB) | 2016-07-12 | — | — | US | disclosed |
| US-20160032378-A1 | MODIFIED NUCLEOTIDES | SOLEXA LIMITED (GB) | 2016-02-04 | — | — | US | disclosed |
| US-9121060-B2 | Modified nucleotides | ILLUMINA CAMBRIDGE LIMITED (GB) | 2015-09-01 | — | — | US | disclosed |
| US-20130197209-A1 | MODIFIED NUCLEOTIDES | ILLUMINA CAMBRIDGE LIMITED (GB) | 2013-08-01 | — | — | US | disclosed |
| US-20120095201-A1 | MODIFIED NUCLEOTIDES | ILLUMINA CAMBRIDGE LIMITED (GB) | 2012-04-19 | — | — | US | disclosed |
| US-8071739-B2 | Modified nucleotides | ILLUMINA CAMBRIDGE LIMITED (GB) | 2011-12-06 | — | — | US | disclosed |
| US-20100292452-A1 | Modified nucleotides | ILLUMINA CAMBRIDGE LTD | 2010-11-18 | — | — | US | disclosed |
| US-7771973-B2 | sequencing reactions where nucleotide or nucleoside molecules modified by reversible covalent attachment of 3'-OH blocking groups thereto, are used where blocked nucleotide or nucleoside molecules are required | ILLUMINA CAMBRIDGE LIMITED (GB) | 2010-08-10 | — | — | US | disclosed |
| US-20090325172-A1 | Modified nucleotides | SOLEXA LIMITED | 2009-12-31 | — | — | US | disclosed |
| US-7541444-B2 | Modified nucleotides | ILLUMINA CAMBRIDGE LIMITED (GB) | 2009-06-02 | — | — | US | disclosed |
| US-20070166705-A1 | Modified nucleotides | ILLUMINA CAMBRIDGE LIMITED (GB) | 2007-07-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100292452-A1 | Modified nucleotides | ADAR, NT5C2, NSUN2 | ALB 4765/4885DNMT1 241/4885ADRB1 2083/4885 |
| US-20160362737-A1 | MODIFIED NUCLEOTIDES | ADAR, NT5C2, NSUN2 | ALB 4766/4885DNMT1 235/4885ADRB1 2081/4885 |
| US-20130197209-A1 | MODIFIED NUCLEOTIDES | ADAR, NT5C2, NSUN2 | ALB 4765/4885DNMT1 241/4885ADRB1 2083/4885 |
| US-20120095201-A1 | MODIFIED NUCLEOTIDES | RNMT, NSUN2, NSUN3 | ALB 3428/4885DNMT1 173/4885ADRB1 2971/4885 |
| US-20070166705-A1 | Modified nucleotides | NT5C2, ADAR, DUT | ALB 4747/4885DNMT1 246/4885ADRB1 2053/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.